Compare Sana Biotechnology Inc (SANA) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Global X Defense Tech ETF — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Global X Defense Tech ETF trades at $59.87 (market cap $6.29B). The key difference: Global X Defense Tech ETF is far larger — about 7.5× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,133,252). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Global X Defense Tech ETF for 44 Days on average.
| SANA | SHLD | |
|---|---|---|
Market Cap | $836.71M | $6.29B |
Volume | 4,507,444 | 1,133,252 |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $78.02 |
52-Week Low | $2.68 | $58.20 |
Typical Hold Time | 23 Days | 44 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
SHLD (Global X Defense Tech ETF) trades at $59.87, up 1.92% today, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF focuses on defense technology with exposure to global defense firms, benefiting from increased defense spending trends. Recent institutional buying activity indicates growing investor interest in the defense sector.
The outlook for SHLD appears mixed - strong geopolitical tailwinds support defense spending growth, but technical weakness suggests near-term pressure. Key opportunities include exposure to rising global defense budgets, while risks involve sector volatility and geopolitical uncertainties affecting defense stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
